In pancreatic cancer, high expression of K17 predicts cellular resistance to chemotherapeutic agents, and podophyllotoxin inhibits the viability of K17-positive PDAC cells and is effective in reducing tumor volume when combined with gemcitabine [90]. Here, KRT17 is linked to neoplasm.